Royalty Report: Drugs, Disease, Therapeutic – Collection: 198450

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • cardiac
  • Molecular
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 198450

License Grant
The Netherland Licensor parties granted the Licensee a royalty-bearing, worldwide license under patent rights and know-how with respect to the  Duchenne muscular dystrophy program, which are potentially necessary or useful for the treatment of DMD,  in all fields of use and for all purposes, including to develop and commercialize antisense oligonucleotide products that target one or more exons of the dystrophin gene to induce exon skipping, including eteplirsen.
License Property
IP includes the disease-modifying pipeline of exon-skipping drug candidates targeting Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.
Field of Use
The Licensee is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.

IPSCIO Record ID: 212182

License Grant
The Netherlands Licensor agreed to provide the Licensee with an exclusive license to certain intellectual property with an option to convert the exclusive license into a co-exclusive license and the Settlement Parties agreed to stop most existing efforts to continue with ongoing litigation and opposition and other administrative proceedings concerning Licensee’s intellectual property.

Th parties entered into an agreement pursuant to which all legal actions in the U.S. and certain legal actions in Europe would be stopped or withdrawn as between the Settlement Parties. Under the terms of the License Agreement and the Settlement Agreement, the company agreed to make up-front payments.  Additionally, the company may be liable for regulatory and sales milestones for eteplirsen as well as exon 45 and exon 53 skipping product candidates.  The Parties will also be eligible to receive royalty payments for exon 51 skipping products, exon 45 skipping products and exon 53 skipping products.

License Property
EXONDYS 51, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen and is marketed in the U.S. under the trademarked name of EXONDYS 51® (eteplirsen) Injection.
Field of Use
Disease-modifying pipeline of exon-skipping drug candidates targeting DMD.

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. DMD is one of four conditions known as dystrophinopathies.

EXONDYS 51 uses Licensee's proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. EXONDYS 51 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein. Data from clinical studies of EXONDYS 51 in a small number of DMD patients have demonstrated a consistent safety and tolerability profile. The pivotal trials were not designed to evaluate long-term safety and a clinical benefit of EXONDYS 51 has not been established.

IPSCIO Record ID: 200059

License Grant
The Agreements provide the Licensee with global exclusive rights to the Licensors Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. The Agreements resolved the ongoing worldwide patent proceedings related to the use of EXONDYS 51 and all future exon-skipping products for the treatment of DMD.
License Property
Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51.
Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown of skeletal muscles over time.
Field of Use
Commercialization of pharmaceuticals for the treatment of neuromuscular diseases.

IPSCIO Record ID: 289156

License Grant
The Netherland Licensor hereby grants to English Licensee, and Licensee hereby accepts and shall have with effect from the Effective Date, an exclusive (even as to Licensor and its Affiliates), worldwide sublicenseable license in the Territory under all of Licensor’s and its Affiliates’ rights, title and interest in and to the Exclusively Licensed IP pertaining to the Exon 51 Program and/or to any Compound(s) therein to make, have made, use, sell, offer for sale and import Compounds under the Exon 51 Program as and into Licensee Products in the Field.
License Property
Compound means any of (i) each of PRO051 and PRO044 and (ii) compounds comprising an antisense oligonucleotide (AON) that is directed to exon skipping by a mechanism intended to directly induce single exon skipping in the dystrophin gene for the treatment of DMD for the relevant exons of the Exon 51 Program, the Exon 44 Program, the DMD Program 3, or the DMD Program 4, as applicable, and meeting the criteria set by the JSC  (Joint Steering Committee for the relevant Licensor Collaboration Program, unless otherwise mutually agreed by the JSC, and, in the case of (i) or (ii), all derivatives and improvements of such compound, (a) that are existing as of the Effective Date or (b) that are Researched and/or Developed by Licensor under a Licensor Collaboration Program or (c) as identified, further modified, optimized or otherwise Researched or Developed by Licensee under a Licensee Development Program.

PRO044 means a 2’-O-methyl-phosphoro-thioate-oligoribonucleotide with sequence 5’-UCA GCU UCU GUU AGC CAC UG-3’.

“PRO051 means a 2’-O-methyl-phosphoro-thioate-oligoribonucleotide with sequence 5’-UCA AGG AAG AUG GCA UUU CU-3’.

Exon 51 Program means a program of Research and Development activities for Licensor’s proprietary Compounds targeted to specific exons of the human dystrophin gene existing as of the Effective Date or arising under this Agreement that are intended to treat DMD by a mechanism of single exon-skipping intended to induce cells to specifically skip translation of exon 51 of the dystrophin gene, including the Lead Compound “PRO051” and any other Compounds that are Researched or Developed by or on behalf of Licensor or its Affiliate qualifying under this definition.

DMD means Duchenne Muscular Dystrophy.

Exclusively Licensed IP means (i) with respect to each Compound in the Exon 51 Program, and (ii) with respect to each Compound in a Licensor Collaboration Program for which Licensee exercises the Option and receives rights upon exercise pursuant to or by operation of the applicable provisions, in the case of either (i) or (ii) above shall include both (a) and (b) as follows (a) any and all Licensor Know-How and Joint Know-How, in each case that describes the composition of matter of or is necessary or useful for the making, use (including method of use) or sale of such Compound, and (b) any and all Licensor Patent Rights and Joint Patent Rights, in each case that claims or covers the composition of matter of or the making, use (including method of use) or sale of any such Compound.

Licensee Product means a Product Developed and commercialized by Licensee or its Affiliate or Sublicensee under or resulting from a Licensee Development Program.

Licensee Development Program means each of (i) the Exon 51 Program, and (ii) any Licensor Collaboration Program for which Licensee has exercised its Option and, for both (i) and (ii), where such Program has not been terminated by Licensee or terminated by Licensor (i.e for a termination by Licensor in the case of an uncured material breach by Licensee of its diligence or other obligations with respect to such Program).

Exon 51 Program means a program of Research and Development activities for Licensor’s proprietary Compounds targeted to specific exons of the human dystrophin gene existing as of the Effective Date or arising under this Agreement that are intended to treat DMD by a mechanism of single exon-skipping intended to induce cells to specifically skip translation of exon 51 of the dystrophin gene, including the Lead Compound “PRO051” and any other Compounds that are Researched or Developed by or on behalf of Licensor or its Affiliate qualifying under this definition.

Exon 44 Program means a program of Research and Development activities for Licensor’s proprietary Compounds targeted to specific exons of the human dystrophin gene existing as of the Effective Date or arising under this Agreement that are intended to treat DMD by a mechanism of single exon-skipping intended to induce cells to specifically skip translation of exon 44 of the dystrophin gene, including the Lead Compound “PRO044” and any other Compounds that are Researched or Developed by or on behalf of Licensor or its Affiliate qualifying under this definition.

DMD Program 3 means a program of Research and Development activities for Licensor’s proprietary Compounds targeted to specific exons of the human dystrophin gene existing as of the Effective Date or arising under the collaboration that are directed to exon skipping by a mechanism intended to directly induce single exon skipping in the dystrophin gene for the treatment of DMD by inducing cells to specifically skip translation of a mutually agreed exon(s) of the dystrophin gene, including any Secondary Compounds developed by Licensor.

DMD Program 4 means a program of Research and Development activities for Licensor’s proprietary Compounds targeted to specific exons of the human dystrophin gene existing as of the Effective Date or arising under the collaboration that are directed to exon skipping by a mechanism intended to directly induce single exon skipping in the dystrophin gene for the treatment of DMD by inducing cells to specifically skip translation of a mutually agreed exon(s), but exon(s) that are different from the exon(s) of DMD Program 3, of the dystrophin gene and any Secondary Compounds developed by Licensor.

Licensor Collaboration Program means each of Licensor’s programs of Research and Development activities for Compounds targeted to specific exons of the human dystrophin gene, and collectively, the Licensor Collaboration Programs includes the “Exon 44 Program”, the “DMD Program 3” and the “DMD Program 4”.

Licensee Development Program means each of (i) the Exon 51 Program, and (ii) any Licensor Collaboration Program for which Licensee has exercised its Option and, for both (i) and (ii), where such Program has not been terminated by Licensee or terminated by Licensor (i.e for a termination by Licensor in the case of an uncured material breach by Licensee of its diligence or other obligations with respect to such Program).

Field of Use
This agreement pertains to the development and commercializeation of RNA-based therapeutics for the treatment of DMD (Duchenne muscular dystrophy).

Duchenne muscular dystrophy (DMD) is a progressive form of muscular dystrophy that occurs primarily in males, though in rare cases may affect females. DMD causes progressive weakness and loss (atrophy) of skeletal and heart muscles.

IPSCIO Record ID: 289155

License Grant
Netherlands University hereby grants to Netherlands Licensee an exclusive right and license under the University Patent Rights, University’s interest in the Joint Patent Rights and the University Tangible Technology without any limitation as to a field of application to develop, make, have made, use, offer for sale, sell, have sold, import and export the Products within the Territory. Said license includes the right to grant sublicenses.

University hereby grants to Licensee a non-exclusive right and license, with the right to sublicense, to use the University Technology other than the University Tangible Technology without any limitation as to a field of application to develop, make, have made, use, offer for sale, sell, have sold, import and export the Products within the Territory.

License Property
Products shall mean any product that harbors the University Technology or the manufacture, development, use, marketing and/or sale of which would infringe, on a country by country basis, all or some of the Valid Claims of the University Patents or Joint Patent Rights if no license would have been granted hereunder.

University Patent Rights shall mean the Patent Rights exclusively owned by University and identified and named hereto.
Series 1 – Exon Skipping
Series 2 – Multiskip
Series 3 – Exon SR Skipping
Series 4 – Double Targeting
Serie 9 – BMP4

University Tangible Technology shall mean the standard operation procedures and/or other information and/or materials described.

University Technology shall mean the Technology which is useful for the development, production and/or commercialization of the Products and which has been discovered, made or conceived solely by University employees, agents or consultants in the research group of Prof. Van Ommen and have been shared by University with Licensee before the Effective Amendment Date and which is described hereto.
Patient material e.d.
AON
Animals
Lab technology

Field of Use
The Parties have entered into a research and license agreement dated September 1, 2003, aimed at the (further) development and commercialization of a treatment against Duchenne Muscular Dystrophy.  Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. DMD is one of four conditions known as dystrophinopathies.

IPSCIO Record ID: 784

License Grant
The Australian Licensor grants the Licensee the exclusive, worldwide License, with the right to grant sublicenses to conduct research in the Field to develop various products for the treatment of Duchenne Muscular Dystrophy by inducing the skipping of certain exons for which the Patent Rights and Technical Information may be useful.
License Property
Patent Rights shall mean International PCT Patent Application No. PCT/AU2005/000943, filed on June 28, 2005 and published as PCI’ Publication No. WO 2006/000057. The Patent Rights are all owned by the Licensor.
Field of Use
Field of Use shall mean the treatment of Duchenne Muscular Dystrophy by inducing the skipping of the Exons of Interest and/or by skipping blocks of exons that include any or all of the Exons of Interest through the use of those antisense sequences listed in the Patent Rights.

IPSCIO Record ID: 27797

License Grant
Licensor hereby grants to Licensee, a Japanese corporation, an exclusive license in the Territory under Patents, Technical Information and the Trademark to develop, have developed, use, have used, make, have made, sell, have sold, distribute and have distributed the Product in the Field, with the right to grant sublicenses.
License Property
Licensee has an interest in the exclusive development of such technologies for the use of Myodur tm brand Product (as hereinafter defined) in the treatment of muscular dystrophy.

Product shall mean the combination of carnitine and leupeptin (and any analogues, conjugates or derivatives thereof) designated by Licensor as the Myodur brand.

Trademark shall mean the Myodur brand as used on and in relation to the Product.

Muscular dystrophy (MD) is a group of muscle diseases that weaken the musculoskeletal system and hamper locomotion.[1][2] Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue.

US Patent 4,742,081 [carnitine]US Patents 4,866,040, 5,008,288 and 5,876,747 [carnitine, aminocarnitine and cysteic acid (taurine)]US and worldwide Patent application for MYODUR specifically in the field of Muscular Dystrophy

Field of Use
Field shall mean Muscular Dystrophy including but not limited to Duchenne's Muscular Dystrophy (DMD) and Becker's Muscular Dystrophy (BMD).

IPSCIO Record ID: 339531

License Grant
The parties amend certain terms of the original License Agreement in light of the sublicensee agreements.

The First Amendment has been amended to include but not limited to License Product, Regulatory Exclusivity, Sublicensee Royalty Term, Sublicensee Product and Royalty payments.

License Property
Patent applications relates to a novel synthetic microdystrophin gene to make, sell and distribute products for use in the treatment of Duchene and related disease indications resulting from a lack of functional dystrophin.

Licensed Product) is amended by adding (a) Any product, apparatus, kit, composition, or component thereof (i) whose use, sale, offer for sale, or importation of which is covered, in whole or in part, by any valid claim contained in the Patent Rights or (ii) which is made by any method, procedure, process, or step which is covered, in whole or in part, by any valid claim contained in the Patent Rights; or (b) An isolated synthetic nucleic acid molecule comprising a synthetic mini-dystrophin or micro-dystrophin gene encoding a synthetic, non-full-length, dystrophin protein that is able to restore nNOS to the sarcolemma, wherein the non-full-length dystrophin protein comprises, from the N terminus to the C terminus 1. the N-terminal domain of the dystrophin protein or a modified N-terminal domain of the dystrophin protein, 11. at least two repeats of the mid-rod domain of the dystrophin protein, wherein said at least two repeats comprise R16 and Rl 7, 111. at least 2 hinge regions of the dystrophin protein, whereas said at least two hinge regions comprise HI and H4, and 1v. the cysteine-rich domain of the dystrophin protein; wherein the mini- or micro-dystrophin gene is between 5 kb to about 8 kb in length or less than 5 kb in length, respectively.

Duchenne is caused by mutations in the dystrophin gene, which result in the absence or near-absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and tear. Without functioning dystrophin and certain associated proteins, muscles suffer excessive damage from normal daily activities and are unable to regenerate, leading to the build-up of fibrotic, or scar, and fat tissue. Efforts are focused on our lead product candidate, SGT-001, a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patients’ muscles and improve the course of the disease. Based on our preclinical program that included multiple animal species of different phenotypes and genetic variations, as well as preliminary clinical trial biomarker results, we believe that SGT-001, has the potential to slow or even halt the progression of Duchenne, regardless of the type of genetic mutation or stage of the disease.

Sublicensee Product means any Licensed Product commercialized by Sublicensee, its affiliates or permitted sublicensees pursuant to the Collaboration and License Agreement, dated October 22, 2020, by and between Sublicensee and Licensee.

SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy designed to address the underlying genetic cause of Duchenne muscular dystrophy (Duchenne). Duchenne is caused by mutations in the dystrophin gene that result in the absence or near absence of dystrophin protein. SGT-001 is a systemically administered candidate that delivers a synthetic dystrophin gene, called microdystrophin, to the body. This microdystrophin encodes for a functional protein surrogate that is expressed in muscles and stabilizes essential associated proteins, including neuronal nitric oxide synthase (nNOS). Data from Solid’s preclinical program suggests that SGT-001 has the potential to slow or stop the progression of Duchenne, regardless of genetic mutation or disease stage.

Field of Use
Field of use is for the cure Duchenne muscular dystrophy (“Duchenne”), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Duchenne is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births.  SGT-001 is our lead gene transfer candidate and the focus of our research and development efforts. Gene transfer, a type of gene therapy, is designed to address diseases caused by mutated genes through the delivery of functional versions of those genes, called transgenes. The transgenes are then utilized by the body to produce proteins that are absent or not functional prior to treatment, potentially offering long-lasting beneficial clinical effects.

IPSCIO Record ID: 239657

License Grant
License grants the Licensee  exclusive, worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional protein.   License also grants rights to five additional investigational gene therapy products for neurological conditions.
License Property
An investigational Silence-and-Replace gene therapy program for the treatment of oculopharyngeal muscular dystrophy.  The Silence-and-Replace gene therapy technology is designed to deliver a combination of DNA-directed RNA interference (silence) along with a functional copy of the gene (replace) in a single vector construct.
Field of Use
The AXO-AAV-OPMD Program is an investigational gene therapy being developed as a one-time treatment for oculopharyngeal muscular dystrophy.

Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.

IPSCIO Record ID: 190271

License Grant
Licensor granted an exclusive worldwide option and collaboration agreement under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of spinal muscular atrophy or SMA.  Licensee exercised the option to develop and commercialize SPINRAZA.
License Property
SPINRAZA is an antisense oligonucleotide. Antisense drugs are small snippets of synthetic genetic material that bind to ribonucleic acid (RNA), so they can be used to fix splicing errors in genes such as SMN2.

SPINRAZA is approved by the U.S. Food and Drug Administration for the treatment of SMA in pediatric and adult patients in the U.S.

Spinal muscular atrophy (SMA) is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.

Field of Use
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

Licensee is a biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.

IPSCIO Record ID: 256305

License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensor Patents, the Isis Splicing Patents and/or the Licensee Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.

The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.

Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).

Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

IPSCIO Record ID: 256513

License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensee Patents, the Isis Splicing Patents and/or the Licensor Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.

The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.

Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).

Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

IPSCIO Record ID: 26664

License Grant
The Licensor has granted the Licensee an exclusive License for human applications of our GDF portfolio. The Licensee has a significant development program for Myostatin based on this License. Phase II clinical trials for Myostatin as a therapeutic for treatment of Muscular Dystrophy have been completed.
License Property
Myostatin is being evaluated for treatment of other muscle degenerative diseases, including muscle wasting called Cachexia, age related muscle loss or Sarcopenia, Lou Gehrig’s disease or ALS, and metabolic disorders such as Type II Diabetes and obesity.
Field of Use
The rights granted apply to pharmaceutical companies for human health applications.

IPSCIO Record ID: 289172

License Grant
The Canadian Licensor, a non-profit academic health research institute, grants to the Canadian Licensee the exclusive, world-wide, right and license, with the right to sublieense, to use Licensors rights in and to the Licensed Technology and the Licensed Patents in the Field of Use to develop Licensed Products and to make, have made, import, use, offer for sale and sell Licensed Products.
License Property
License relates to certain patents relating to the use of Wnt7a proteins.

Licensor owns technologies relating to protein and small molecule therapies for the treatment of diseases.

1. A Pax-Encoding Vector And Use Thereof US (CIP) 7,384,784

2. Methods And Compositions For Modulating Stem Cell Growth And Differentiation US 7,541,183

3. Novel Stem Cells, Nucleotide Sequences And Proteins Therefrom US 12/094,585

4. Use Of Cardiotropbln To Modulate Stem Cell Proliferation US 11/318,413

5. Pancreatic Regeneration PCT/CA2009/001220

6. Treatment of Muscle Disease Characterized by Insulin Resistance US Provisional 61/179,040

7. Composition and Methods for Modulating Stem Cells US Provisional 61/172,832

8. Cardiac Stem Cell Proliferation Proteins, Fragments Thereof And Methods Of Modulating Stem Cell Proliferation And Differentiation US 12/156,953

9. Prodrugs of Biguanlde Derlvatlves For The Treatment of Muscular Disorders US Provisional 61/244,669

Field of Use
Licensee has identified Wnt7a as a natural promoter of SSCs to drive muscle regeneration and are initially focused on developing Wnt7a protein analogs for the treatment of muscular dystrophies. Licensee believes that our regenerative approach for treating muscular dystrophies holds significant therapeutic promise and is distinct from other approaches, which focus on preventing muscle degeneration.

Field of Use means all fields.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.